Evolving DLBCL Treatment Landscape: Interpreting ASH 5-Year Polatuzumab Data in Clinical Practice
Experts discuss the evolving treatment landscape of DLBCL, emphasizing the interpretation of 5-year Polatuzumab data presented at ASH and its implications for clinical practice.
EP. 1: Advances in DLBCL Management: Long-Term Treatment Outcomes
March 31st 2025Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting its meaningful progression-free survival (PFS) and overall survival (OS) results for first-line patients with DLBCL and emphasizing key long-term safety considerations for clinicians.
Watch
EP. 2: Long-Term Outcomes and Treatment Guidelines in DLBCL Management
March 31st 2025Experts discuss how the 5-year outcomes of polatuzumab have influenced its position in current NCCN guidelines for diffuse large B-cell lymphoma (DLBCL) treatment, offering insights on how to interpret and apply these recommendations in various patient scenarios.
Watch
